Alector, Inc. (ALEC): Price and Financial Metrics

Alector, Inc. (ALEC): $9.16

0.19 (+2.12%)

POWR Rating

Component Grades













Add ALEC to Watchlist
Sign Up

Industry: Biotech



in industry

ALEC Stock Price Chart Interactive Chart >

Price chart for ALEC

ALEC Price/Volume Stats

Current price $9.16 52-week high $17.68
Prev. close $8.97 52-week low $6.84
Day low $8.95 Volume 363,704
Day high $9.28 Avg. volume 622,450
50-day MA $8.61 Dividend yield N/A
200-day MA $9.60 Market Cap 757.55M

Alector, Inc. (ALEC) Company Bio

Alector, Inc. operates as a clinical-stage biopharmaceutical company. It develops therapeutics for the treatment of neurodegenerative diseases including frontotemporal dementia (FTD), Alzheimer's disease, and Parkinson's disease. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA

ALEC Latest News Stream

Event/Time News Detail
Loading, please wait...

ALEC Latest Social Stream

Loading social stream, please wait...

View Full ALEC Social Stream

Latest ALEC News From Around the Web

Below are the latest news stories about Alector Inc that investors may wish to consider to help them evaluate ALEC as an investment opportunity.

Cyclerion Therapeutics: Distressed Spinoff Developing New Medicines For CNS Disorders

Source: Company Summary Cyclerion Therapeutics (CYCN) is a spinoff from Ironwood Pharmaceuticals (IRWD) with several clinical failures over the last few years and a strong management team. This distressed situation creates an interesting investment opportunity pending clinical data for the company’s lead asset, CY6463. In 2019, under the pressure of...

Numenor Capital on Seeking Alpha | NA NA, NA

Homology Medicines: In Vivo Gene Therapy Platform With Delayed Lead Trial Coming Back Online

Source: Company Summary Homology Medicines (FIXX) is a gene therapy and editing platform company centered around hematopoietic stem cells (“HSC”). The investment thesis for Homology builds on top of past analysis on Orchard Therapeutics (ORTX) to use HSCs to potentially cure immune-related disease - Orchard Therapeutics: For Immune-Related Disease (NASDAQ:ORTX)...

Numenor Capital on Seeking Alpha | NA NA, NA

Read More 'ALEC' Stories Here

ALEC Price Returns

1-mo 3.97%
3-mo -3.78%
6-mo -10.37%
1-year -35.04%
3-year -62.75%
5-year N/A
YTD -0.76%
2022 -55.30%
2021 36.48%
2020 -12.19%
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5943 seconds.